- Home
- NN vs AGIO Comparison
NN vs AGIO Comparison
Compare NN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NN
- AGIO
- Stock Information
- Founded
- NN 2007
- AGIO 2007
- Country
- NN United States
- AGIO United States
- Employees
- NN N/A
- AGIO N/A
- Industry
- NN Industrial Machinery/Components
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- NN Industrials
- AGIO Health Care
- Exchange
- NN Nasdaq
- AGIO Nasdaq
- Market Cap
- NN 2.2B
- AGIO 2.0B
- IPO Year
- NN N/A
- AGIO 2013
- Fundamental
- Price
- NN $12.99
- AGIO $32.42
- Analyst Decision
- NN
- AGIO Buy
- Analyst Count
- NN 0
- AGIO 7
- Target Price
- NN N/A
- AGIO $56.33
- AVG Volume (30 Days)
- NN 1.8M
- AGIO 1.0M
- Earning Date
- NN 03-12-2025
- AGIO 02-13-2025
- Dividend Yield
- NN N/A
- AGIO N/A
- EPS Growth
- NN N/A
- AGIO N/A
- EPS
- NN N/A
- AGIO 11.80
- Revenue
- NN $4,963,000.00
- AGIO $32,871,000.00
- Revenue This Year
- NN $46.32
- AGIO $33.41
- Revenue Next Year
- NN $43.50
- AGIO $172.14
- P/E Ratio
- NN N/A
- AGIO $2.75
- Revenue Growth
- NN 43.44
- AGIO 36.79
- 52 Week Low
- NN $3.55
- AGIO $20.96
- 52 Week High
- NN $18.54
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- NN 40.15
- AGIO 33.53
- Support Level
- NN $12.33
- AGIO $32.85
- Resistance Level
- NN $13.48
- AGIO $35.03
- Average True Range (ATR)
- NN 1.31
- AGIO 1.75
- MACD
- NN -0.28
- AGIO 0.48
- Stochastic Oscillator
- NN 33.38
- AGIO 22.40
About NN NextNav Inc.
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation and Timing services in the absence of GPS.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.